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ABSTRACT
Interferon tau (IFNT), a type I IFN similar to alpha IFNs
(IFNA), is the pregnancy recognition signal produced by the
ruminant conceptus. To elucidate specific effects of bovine IFNT
and of other conceptus-derived factors, endometrial gene
expression changes during early pregnancy were compared to
gene expression changes after intrauterine application of human
IFNA2. In experiment 1, endometrial tissue samples were
obtained on Day (D) 12, D15, and D18 postmating from
nonpregnant or pregnant heifers. In experiment 2, heifers were
treated from D14 to D16 of the estrous cycle with an
intrauterine device releasing IFNA2 or, as controls, placebo
lipid extrudates or PBS only. Endometrial biopsies were
performed after flushing the uterus. All samples from both
experiments were analyzed with an Affymetrix Bovine Genome
Array. Experiment 1 revealed differential gene expression
between pregnant and nonpregnant endometria on D15 and
D18. In experiment 2, IFNA2 treatment resulted in differential
gene expression in the bovine endometrium. Comparison of the
data sets from both studies identified genes that were
differentially expressed in response to IFNA2 but not in response
to pregnancy on D15 or D18. In addition, genes were found that
were differentially expressed during pregnancy but not after
IFNA2 treatment. In experiment 3, spatiotemporal alterations in
expression of selected genes were determined in uteri from
nonpregnant and early pregnant heifers using in situ hybridiza-
tion. The overall findings of this study suggest differential effects
of bovine IFNT compared to human IFNA2 and that some
pregnancy-specific changes in the endometrium are elicited by
conceptus-derived factors other than IFNT.
endometrium, hormone action, pregnancy, reproductive
immunology, uterus
INTRODUCTION
Interferons (IFNs) play a major role in establishment of
pregnancy and conceptus (embryo and associated extraembry-
onic membranes) implantation in many, if not all, mammalian
species [1–4]. Specific type I IFNs have evolved in several
mammalian groups, such as delta IFNs in horses [5] and in pigs
[3] and IFN tau (IFNT) in ruminants [6–9]. In some mammals
(e.g., mice and pigs), IFN gamma, a type II IFN, has been
implicated in regulation of conceptus implantation/attachment
[10]. Type I and/or type II IFNs produced by trophoblast cells
of the elongating conceptus induce the expression of a variety
of IFN-stimulated genes (ISGs) in the endometrium during the
peri-implantation period, which together with progesterone
(P4)-induced genes are involved in many processes related to
endometrial receptivity, such as attachment of the embryo to
the endometrium surface, trophoblast outgrowth and prolifer-
ation, modulation of the maternal immune system, differenti-
ation of uterine stromal cells, increased endometrial
vascularization, transport of nutrients into the uterine lumen,
and enhanced exchange of molecules between the conceptus
and mother [4].
Produced by trophoblast cells, IFNT has a main function as
the pregnancy recognition signal in ruminants that protects the
functional corpus luteum (CL) [11]. IFNT is secreted in
amounts coordinate with growth and development of the
conceptus during elongation [8, 12], and it acts on the
endometrial luminal epithelium (LE) to suppress transcription
of the estrogen receptor alpha and oxytocin receptor genes in
the endometrium, thereby preventing the uterus from producing
luteolytic pulses of prostaglandin F
2alpha
(PGF2a) [13]. IFNT
induces expression of a number of classical ISGs and increases
expression of a number of P4-induced genes, thereby
influencing a variety of processes in the endometrium related
to endometrial receptivity, including modulation of the
maternal immune system [14]. Very recently, IFNT was
demonstrated to be released from the uterus into the circulation
and to induce ISGs in the CL. Circulating IFNT is thought to
initiate a peripheral antiviral response and to induce luteal
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resistance to PGFa via endocrine mechanisms contributing to
longer-term survival of the CL and maintenance of pregnancy
[15].
Similar to other classical type I IFNs, IFNT acts via the type
I IFN alpha receptor dimer (IFNAR1/2) [16]. Whereas some
authors showed that bovine IFNT and bovine IFN alpha
(IFNA) bind to the same receptor with similar dissociation
constants [17], others found a lower binding affinity of IFNT
compared to IFNA [18]. With regard to estrous cycle
extension, similar effects were shown for IFNA and IFNT in
sheep when equivalent bioactivity doses (antiviral activity)
were given [19]. Thus, the uniqueness of IFNT is thought to be
its developmentally related expression regulation rather than
any special biopotency, although IFNT appears to have less
cytotoxic effects compared to IFNA based on in vitro and in
vivo studies [18, 20]. Similar to sheep, infusion of recombinant
bovine IFNA into the uterus delayed luteolysis in cyclic cows
[21]. Various studies showed binding of human IFNA to ovine
IFNAR [22, 23], and similar effects of human IFNA and ovine
IFNT on release of prostaglandin E and PGF2a from cultured
ovine endometrial cells have been found [24]. A number of
microarray studies have been performed to characterize the
highly complex responses of the endometrium at the level of
gene expression during early pregnancy or after administration
of IFNT in cattle [25–30] and in sheep [31–33]. These studies
revealed large numbers of differentially expressed genes
(DEGs) in the endometrium in response to P4, IFNT, and the
conceptus, suggesting that a number of biological processes
and pathways play a role in the establishment and maintenance
of pregnancy in ruminants.
The present microarray study was conducted to analyze
differential gene expression in bovine intercaruncular endo-
metrium during the preimplantation phase and to compare the
results obtained with the effects of a ‘‘standard’’ type I IFN to
identify specific effects of IFNT and/or additional conceptus-
derived factors. To accomplish this, gene expression in bovine
endometrium was analyzed on Day (D) 12, D15, and D18 of
pregnancy and corresponding nonpregnant control stages,
where D12 was chosen as the time immediately before
conceptus elongation, D15 as a time point during conceptus
elongation and increasing secretion of IFNT, and D18 as the
time before conceptus implantation. In the second experiment,
endometrial gene expression was analyzed after administration
of human IFNA2 or controls from D14 to D16 of the estrous
cycle, the period of maternal recognition of pregnancy, using
slow-releasing lipid extrudates. The comparison of the results
of both experiments identified genes that differ in their
response to pregnancy and their response to IFNA2, suggesting
specific effects of IFNT and/or modulatory effects of other
conceptus-derived factors.
MATERIAL AND METHODS
Preparation of Recombinant Human IFNA2 Containing
Lipid Extrudates
Triglyceride-based lipid twin-screw extrudates were prepared from powder
mixtures of two lipids (D118, glycerol tristearate; H12, mixed-acid triglyceride
comprising lauric, myristic, and palmitic acids; Sasol GmbH, Witten,
Germany), a pore-forming excipient (hydroxypropyl-b-cyclodextrin; Merck,
Darmstadt, Germany), and recombinant human IFNA2 lyophilizate (1:3 with
hydroxypropyl-b-cylcodextrin; Roferon; Roche Diagnostics, Penzberg, Ger-
many) as described by Schulze and Winter [34]. In brief, H12, D118, mannitol
(30%), and IFNA2 lyophilizate (2%) were admixed in an agate mortar, fed into
the barrel of a Minilab Micro Rheology Compounder (Thermo Haake GmbH),
and extruded with a closed-bypass channel through the extruder outlet die (1.9
mm, 40 rpm, 418C; twin screw extruder, MiniLab Micro Rheology
Compounder, Thermo Haake GmbH, Karlsruhe, Germany). Rod-shaped
extrudates were cut at a length of approximately 2.0 cm and weighed on an
analytical balance.
Extrudates (n¼ 6) were placed in 1.9 ml of PBS containing 0.05% sodium
azide at pH 6.6 to mimic the pH in the uteri of cows [35]. At predetermined
points, samples were drawn by complete exchange of the incubation medium
and subsequently quantified UV-spectrophotometrically (UV 1000, Thermo
Electron Corporation, Dreieich, Germany; 215 nm) after separation by size-
exclusion high-performance liquid chromatography (TSKgel G3000SWXL
column; Tosoh Biosep, Stuttgart, Germany; flow rate: 0.6 ml/min, Dionex
Ultimate 3000, Dionex GmbH, Idstein, Germany) as described by Mohl and
Winter [36].
IFN Bioassay
The antiviral activity of recombinant human IFNA2 and the antiviral
activity present in uterine flushings were quantified by means of a bioassay
based on the inhibition of the cytopathic effect of vesicular stomatitis virus
(Indiana strain) on Madin-Darby bovine kidney (MDBK; American Type
Culture Collection CRL-6071) cells [37]. The National Institutes of Health
(NIH) recombinant human IFNA2 reference preparation (Gxa01-901-535) was
included in each assay. One unit of IFN per milliliter corresponds to the
quantity necessary for a cytopathic effect of 50% (i.e., 50% inhibition of cell
lysis). Recombinant human IFNA2 (1.56 mg/ml) was diluted 107-fold for the
starting dilution. Uterine flushings were not diluted for the starting dilution of
the assay. Twofold dilutions were performed, and the dilution with a 50%
cytopathic effect corresponded to 1 U of antiviral activity. The antiviral activity
was shown to be IFN, because the effects of uterine flushings and appropriate
control IFN preparations were blocked by specific anti-IFN sera.
Treatment of Heifers and Collection of Endometrial Tissue
Samples
Heifers for experiments 1 and 2 were housed in the facilities of the Bavarian
State Research Center for Agriculture. Treatments of heifers were approved and
performed with permission of the local authorities (District Government of
Upper Bavaria, Germany). Experiments with heifers were performed in
accordance with the International Guiding Principles for Biomedical Research
Involving Animals as proposed by the Society for the Study of Reproduction,
with the European Convention on Animal Experimentation, and with the
German Animal Welfare Act.
Experiment 1: Early pregnancy. The estrous cycles of German Simmental
heifers between 16 and 26 mo old were synchronized by an intramuscular
injection of a single dose of 500 lg of cloprostenol (PGF2a; Estrumate;
Intervet) at diestrus. Presence of a functional CL was checked by transrectal
palpation. Sexual behavior of heifers (i.e., toleration, sweating, and vaginal
mucus) was observed to determine standing heat, which occurred approxi-
mately 60 h after cloprostenol injection. In addition, ultrasound-guided follicle
monitoring was performed to check follicle development. Blood samples were
taken 2 days before estrus (Day2), at estrus (D0), and just before slaughter to
determine P4 concentrations. Heifers without signs of estrus (standing heat)
were excluded. Heifers assigned to the insemination group were inseminated on
D1 with cryopreserved sperm (ejaculate þ diluter, 1:10) of the same bull and
slaughtered at D12, D15, or D18. Cyclic control heifers received sperm-free
supernatant of cryopreserved sperm. Five milliliter of sperm were transferred to
centrifugation vials and centrifuged at 3500 3 g at room temperature for 10
min. Supernatant was transferred to fresh vials and centrifuged again. Absence
of spermatocytes was controlled under a microscope. Sperm supernatant was
then transferred to 0.25 ml semen straws and stored at48C until insemination
a few days later. After slaughter at the corresponding days of the estrous cycle,
collected uteri were trimmed free from surrounding tissue, and uterine horns
were opened longitudinally. In heifers slaughtered on D12, the uteri were
flushed with PBS before opening to determine the presence of a blastocyst. The
D12 control heifers were also flushed. For D15 and D18, pregnancy was
confirmed by presence of a conceptus that was carefully removed before
collecting endometrial tissue samples. Endometrial tissue samples were
collected from the uterine horns ipsilateral to the functional CL (specifically,
from the cranial uterine part for D12 heifers, from the middle part for D15
heifers, and from the caudal part for D18 heifers). Samples were carefully cut
from the lamina propria of the intercaruncular endometrium with a scalpel and
immediately transferred into vials containing 4 ml of RNAlater (Ambion) and
then incubated overnight at 48C. Subsequently, samples were removed from
RNAlater and stored at808C until further processing. For D12, five pregnant
heifers and five controls and, for D15 and D18, four pregnant heifers and four
controls, respectively, were selected for microarray and quantitative real-time










D0, and day of slaughter), state of the ovaries at slaughter, and the presence of a
conceptus in the pregnancy groups.
Experiment 2: Treatment with human IFNA2. The estrous cycles of 15
German Simmental heifers between 23 and 25 mo old were synchronized as
described for experiment 1. Blood samples were taken at the day of
cloprostenol injection (Day 2), at estrus (D0), at D7 and D14 of the estrous
cycle, and daily from D16 to D26 to determine serum P4 concentrations.
Presence of a functional CL was checked on D7 and D14 by transrectal
ultrasonography. Based on P4 concentrations on D7 and results of
ultrasonography, 12 animals were selected and randomly assigned to one of
the following three treatment groups. In the IFNA2 treatment group (IFNA; n¼
4 heifers), a rod-shaped human IFNA2-releasing lipid extrudate was loaded in
PBS into a 0.5-ml artificial insemination straw and nonsurgically (via the
cervix) transferred into the uterine horn ipsilateral to the functional CL on D14
using an insemination pipette. Two control groups were used: The placebo
group (PLAC; n¼ 4) received only the rod-shaped lipid extrudate, whereas the
other control group (CONT; n¼4) received PBS only. Based on in vitro release
experiments, IFNA2 concentration and lipid formulation were adjusted to
release 8–93107 IU of IFNA2 over a period of 2 days. The proposed release of
IFNA2 over the 2-day period was based on data from previous studies with
sheep in which intrauterine applications of IFNT or IFNA have been performed
[19, 38, 39]. On D16 of the estrous cycle, uteri were nonsurgically flushed with
10 ml of PBS using an embryo-flushing catheter (type Dissi, CH12; Minitu¨b).
Flushing medium was collected in 50-ml Falcon tubes (Nunc) and frozen for
estimation of antiviral activity. After flushing, six (6 one) uterine biopsy
samples were collected per heifer from the ipsilateral horn by the use of an
uterine biopsy forceps (type 8151.07; length, 450 mm; diameter, 2.2 mm;
Richard Wolf), which was nonsurgically inserted into the uterine horn through
a self-shortened transcervical plastic cannula (type bovivet; Henry Schein)
under rectal palpation control. The weight of one biopsy sample was
approximately 5 mg. Biopsy samples were pooled for each heifer, transferred
to 1 ml of RNAlater, and incubated overnight at 48C. Subsequently, samples
were removed from RNAlater and stored at 808C until further processing.
Experiment 3: In situ localization of mRNAs in the bovine uterus. As
described previously [40], cross-bred nulliparous beef heifers were artificially
inseminated with semen from a single bull after a timed, artificial insemination
synchronization protocol [41] and then slaughtered on D10, D13, D16, or D19
after mating. The uterus was flushed with 20 ml of sterile 10 mM Tris buffer
(pH 7.2). Heifers were classified as pregnant if the uterine flush contained a
blastocyst/conceptus of the correct morphology and size or as nonpregnant if
the uterine flush did not contain a blastocyst/conceptus. Uterine tissues were
collected from nonpregnant heifers on D10, D13, D16, and D19 (n¼5 per day)
and from pregnant heifers on D13, D16, and D19 (n¼ 6 per day). Portions of
the uterus ipsilateral to the CL were fixed in 4% paraformaldehyde in PBS (pH
7.2) overnight and then embedded in paraffin for immunohistomolecular
analyses.
Affymetrix GeneChip Hybridization and Data Analysis
Total RNA was isolated from endometrial tissue samples using TRIzol
(Invitrogen) according to the manufacturer’s instructions. The quantity and
quality of total RNA was determined using spectrophotometry, agarose gel
electrophoresis, and a Bioanalyzer 2100 (Agilent Technologies). RNA integrity
numbers were 7.6–8.4 for samples from the IFNA experiment, 8.5–9.5 for
samples from D12, 8.3–9.2 for samples from D15, and 8.2–9.0 for samples
from D18. Preparation of hybridization probes for Affymetrix GeneChip
Bovine Genome Arrays (Affymetrix) was performed using 10 lg of total RNA
and the One-Cycle Target Labeling and Control Reagent package (Affymetrix).
For the hybridization, wash, and staining process, the GeneChip Hybridization,
Wash, and Stain Kit (Affymetrix) and a Fluidic Station 450 (Affymetrix) were
used. All steps were done according to the manufacturer’s protocol. The
processed arrays were scanned with a GeneChip Scanner 3000 7G with
AutoLoader (Affymetrix).
Affymetrix CEL files were processed with the robust multiarray average
method [42]. Quality control was done using a variety of tools, such as pseudo-
images (BioC package AffyPLM), RNA degradation plots (BioC package
Affy), different box plots, distance matrices, and heatmaps. Probe sets were
filtered based on expression calls before significance analysis. Only probe sets
were used with present calls in at least three of four (D15 and D18) or four of
five (D12) samples in at least one of the respective experimental groups.
Significance analysis was performed with the function decideTests of the BioC
package Limma [43], and multiple testing correction was done using the
parameter fdr to calculate adjusted P values. Probe set annotation of the bovine
Affymetrix Genome Array was improved based on mapping to the bovine
genome, and the putative human orthologous genes were assigned. If a
transcript was represented on the arrays by more than one probe set, the mean
values for fold-change and adjusted P values were calculated.
For Gene Set Enrichment Analysis (GSEA) [44], genes were preranked
based on expression fold-change (pregnant vs. control) and the adjusted P-
value (log
2
(fold-change þ 2)  log
10
(P value)), resulting in a ranked gene list
containing the most significantly upregulated genes at the top of the list and the
most significantly downregulated genes at the bottom. This preranked gene list
was compared with GSEA gene sets c2.all.v3.symbols.gmt (curated) and other
published gene sets. Classification of DEGs and identification of quantitatively
enriched functional categories were done using different tools of the Database
for Annotation, Visualization, and Integrated Discovery (DAVID) [45].
Identification of biological keywords cocited with DEGs in PubMed abstracts
was performed with CoPub [46]. Analysis of functional databases was based on
the Entrez Gene ID of the putative human orthologous genes.
The data discussed in the present publication have been deposited in the
National Center for Biotechnology Information Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO
Series accession no. GSE30694.
Quantitative Real-Time RT-PCR
The same RNA samples used for microarray analysis were used for qPCR.
First-strand cDNA was synthesized starting from 1 lg of total RNA with the
Sprint RT Complete-Double PrePrimed Kit (Takara Bio Europe/Clontech).
Two-step qPCR experiments were performed as described previously [47] in
accordance with the Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guidelines [48] and using a LightCycler
DNA Master SYBR Green I protocol (Roche). The cycle threshold (Ct)
required for achieving a definite SYBR Green fluorescence signal was
calculated by the second derivative maximum method (LightCycler software
version 3.5.28). The Ct is correlated inversely with the logarithm of the initial
template concentration. The Ct values determined for the target genes were
normalized against the geometric mean of the reference genes H3 histone,
family 3A (H3F3A) and polyubiquitin (LOC281370) (DCT) [49]. Reference
genes were chosen from three potential reference genes (H3F3A, LOC281370,
and GAPDH) based on GeNorm analysis. Finally, the relative expression
differences between the corresponding experimental groups were calculated
(DDCT). All amplified PCR fragments were sequenced to verify the
concordance with the corresponding target sequence. The sequences of the
PCR primers, size of PCR products, annealing temperature, melting point, and
fluorescence acquisition temperature are listed in Supplemental Table S1 (all
Supplemental Data are available online at www.biolreprod.org).
In Situ Hybridization
Cell-specific expression of mRNAs in cross-sections of bovine uteri (n¼ 5
per day and status) from experiment 3 was determined using radioactive in situ
hybridization analysis conducted using methods described previously [50].
Partial cDNAs for bovine endometrial DKK1, FABP3, IDO1, IFI27, and
JHDM1D mRNAs were cloned by RT-PCR using specific primers and then
sequenced to confirm identity (data not shown). All slides for each respective
gene were exposed to photographic emulsion for the same period of time.
Images of representative fields were recorded under bright-field or dark-field
illumination using a Nikon Eclipse 1000 photomicroscope fitted with a Nikon
DXM1200 digital camera.
RESULTS
Antiviral Activity of Human IFNA2 on MDBK Cells, In Vitro
IFNA2 Release Data, and Antiviral Activity in Uterine
Flushings
The antiviral activity of human IFNA2 was evaluated on
MDBK cells to estimate the amount of IFNA2 protein for the
slow-releasing lipid extrudates. This assay revealed that the
recombinant human IFNA2 contained 410 IU/ng protein. Next,
rod-shaped IFNA2-releasing lipid extrudates were produced,
and IFNA2 release was tested in vitro to find the appropriate
lipid formulation for a cumulative release of approximately 93
107 IU over 2 days (Table 1 and Supplemental Fig. S1). To
examine the release in vivo, antiviral activity in uterine
flushings collected on D16 after transfer of lipid extrudates on
D14 was measured. Antiviral activity was not detectable in
PLAC, but 0–160 IU were estimated in CONT and 0.82–6.53
106 IU per flushing in IFNA.










For the D12 nonpregnant controls, serum P4 concentrations
were from 2.7 to 6.0 ng/ml on the day of PGF2a injection,
from less than 0.2 to 0.6 ng/ml on D0, and from 7.2 to 9.9 ng/
ml on D12 of the estrous cycle. The D12 pregnant heifers had
serum P4 concentrations ranging from 3.6 to 4.8 ng/ml on the
day of PGF2a injection, less than 0.2 ng/ml on D0, and from
5.2 to 12.5 ng/ml on D12 after estrus. The D15 nonpregnant
controls showed P4 concentrations ranging from 1.3 to 3.7 ng/
ml on the day of PGF2a injection, from less than 0.2 to 0.8 ng/
ml on D0, and from 1.9 to 8.3 ng/ml on D15 of the estrous
cycle. The P4 concentrations of D15 pregnant heifers were
from 1.2 to 3.7 ng/ml on the day of PGF2a injection, from less
than 0.2 to 0.4 ng/ml on D0, and from 5.2 to 10.4 ng/ml on
D15 after estrus. On D18, P4 concentrations were from 4.1 to
5.9 ng/ml on the day of PGF2a injection, less than 0.2 ng/ml
on D0, and from 3.5 to 7.6 ng/ml on D18 of the estrous cycle
for the control heifers. For the D18 pregnant heifers, P4
concentrations were from 5.1 to 6.7 ng/ml on the day of PGF2a
injection, from less than 0.2 to 0.3 ng/ml on D0, and from 6.3
to 17.9 ng/ml on D18 after estrus. (For individual P4
concentrations, see Supplemental Table S2a.)
For the heifers used in experiment 2 (IFNA study), serum
P4 concentrations were measured at the time of cloprostenol
injection (PGF2a), D0 (estrus), D7, D14, and from D16 to D26
(Supplemental Table S2b). All heifers had basal concentrations
of P4 at D0 (,0.2 ng/ml). However, P4 concentrations were
from 1.2 to 5.0 ng/ml at D7, from 5.2 to 8.6 ng/ml at D14, and
from 3.1 to 7.9 ng/ml at D16. Some heifers showed basal P4
concentrations as early as the period from D11 to D18 (one
heifer in each group). All heifers had basal P4 concentrations
on D23. No significant difference was found between the
treatment groups at any time point. Signs of estrus were
observed between D23 and D26 for all heifers.
Differential Gene Expression at D12, D15, and D18 of
Pregnancy
Messenger RNA abundance in pregnant and cyclic
endometrial tissue samples was analyzed at three different
times of pregnancy: at D12, when the hatched blastocyst has a
diameter of approximately 1 mm; at D15, when the elongated
conceptus has a length of between 3 and 5 cm; and at D18,
when the conceptus trophoblast is beginning to attach to the
endometrial LE [51, 52]. Antiviral activity in bovine uterine
flushings at D12 was not detectable, whereas considerable
amounts were measured at D15 and more than 100-fold higher
amounts at D18 [53].
At D12 of pregnancy, no DEGs were found (adjusted P-
values. 0.1385). Analysis of microarray data for D15 samples
revealed that one sample of the pregnant group (15P) clustered
to the cyclic group (15C) and showed intermediate expression
levels for ISGs. In addition, one cRNA sample of 15C was
identified as an outlier for technical and, probably, biological
reasons (obviously lower serum P4 concentration on D15
compared to the other D15 cyclic controls). These two samples
were omitted for further data analysis, which was done with the
remaining six samples (n ¼ 3 per group). Statistical analysis
resulted in 309 DEGs at D15 of pregnancy (adjusted P value ,
0.05, fold-change . 1.5), of which 245 had higher levels and
64 had lower levels in pregnant endometrium (Supplemental
Table S3). At D18 of pregnancy, 941 differentially expressed
transcripts were identified (adjusted P value , 0.05, fold-
change . 1.5), of which 602 had higher levels and 339 had
lower levels in the D18 pregnant group (18P) (Supplemental
Table S4). A comparison of the DEGs found at D15 and D18
showed that 212 of the 309 DEGs at D15 were also
differentially expressed (false-discovery rate [FDR] ¼ 1%,
fold-change . 1.5) at D18. For the majority of these genes, the
fold-change of mRNA expression was higher at D18
(Supplemental Fig. S2).
TABLE 1. In vitro release of human IFNA2 from lipid extrudates.
Time (h) 13.9 25.0 46.1 72.0 94.1 232.1
Mean cumulative IFNA2 release (mg) 0.148 0.176 0.212 0.229 0.234 0.241
Standard deviation 0.018 0.010 0.0136 0.016 0.017 0.018
Mean cumulative IFNA2 release (106 IU) 60.6 72.2 86.9 94.0 96.0 99.0
Standard deviation 7.4 4.3 5.6 6.7 7.0 7.4
TABLE 2. Selected results of Gene Set Enrichment Analysis of the Day 15 pregnant vs. control data set.







No. genes matching top
300 or bottom (*) 100e
Percent
(%)f
D16 of pregnancy upregulated Forde et al. [28] 285 3.65 ,0.001 ,0.001 779 150 52.6
D17 of pregnancy upregulated Walker et al. [30] 319 3.60 ,0.001 ,0.001 1111 142 44.5
D18 of pregnancy upregulated Klein et al. [25] 66 3.16 ,0.001 ,0.001 196 43 65.2
D18 of pregnancy upregulated (this study) 524 3.81 ,0.001 ,0.001 958 214 40.8
D20 of pregnancy upregulated Mansouri-Attia et al. [29] 36 2.51 ,0.001 ,0.001 163 13 36.1
Browne IFN-responsive genes [90] 51 2.96 ,0.001 ,0.001 284 35 68.6
D16 of pregnancy downregulated Forde et al. [28] 136 2.52 ,0.001 ,0.001 3277 7* 5.1
D17 of pregnancy downregulated Walker et al. [30] 207 1.96 0.004 0.046 2899 3* 1.4
D18 of pregnancy downregulated (this study) 324 3.04 ,0.001 ,0.001 2406 31* 9.6
a Number of genes in a gene set that matched with the ranked gene list.
b NES, normalized enrichment score.
c FDR, false discovery rate.
d FWER, family-wise error rate.
e Number of genes matching with the top 300 or the bottom 100 (designated by italics and an asterisk) of pre-ranked gene list.










Next, GSEA [44] was performed to compare the obtained
data sets for D15 and D18 of pregnancy with results of similar
studies in bovine endometrium from D16, D17, D18, and D20
of pregnancy. GSEA was also used to compare the D15 and
D18 data sets to gene sets of the GSEA Molecular Signature
Database. For the D15 data set, a substantial enrichment toward
the upregulated genes was found for genes that have been
identified as upregulated in bovine intercaruncular endometri-
um on D16 [28], on D17 [30], and on D18 (genes from Klein et
al. [25] and from the present study) of pregnancy (Table 2 and
Supplemental Fig. S3). A moderate enrichment was also found
for genes identified as upregulated on D20 of pregnancy by
Mansouri-Attia et al. [29]. Furthermore, strong enrichment
toward the upregulated genes was found for many gene sets
related to IFN-responsive genes. In contrast, moderate
enrichment toward the downregulated genes was only found
for genes downregulated on D18 identified in the present study.
For the D18 data set, results were similar to those obtained
for the D15 data set for genes found as upregulated on D16,
D17, D18, and D20 of pregnancy and for IFN-responsive genes
(Table 3 and Supplemental Fig. S4). Strong enrichment was
also found for the genes upregulated on D15 of pregnancy.
Moderate enrichment toward the D18 downregulated genes
was observed for genes that have been found as downregulated
on D16 and D17 of pregnancy and for the genes downregulated
on D15 identified in the present study. No significant
enrichment was obtained for the genes identified as downreg-
ulated on D20 of pregnancy by Mansouri-Attia et al. [29] and
other gene sets of the GSEA database except for a few gene
sets related to ribosomal proteins.
The DAVID functional annotation clustering was performed
to characterize the known or inferred functions of the obtained
DEGs for D15 and D18 of pregnancy. Both the D15 and the
D18 upregulated genes revealed almost exclusively overrepre-
sented functional terms related to typical responses to type I
IFNs, such as inflammatory response, defense response,
ubiquitin-like modifier conjugation pathway, proteolysis (com-
plement components, ubiquitin pathway, proteasome subunits),
and cell death. The typical IFN response categories contained
more members on D18 compared to D15 of pregnancy
(Supplemental Table S5). For some categories, members of
gene families came up that were not differential on D15—for
example, members of the chemokine (C-C motif) receptor
family and of the suppressor of cytokine signaling family. The
analysis of the D15 downregulated genes revealed only few
significantly enriched annotation clusters that contained genes
with potential binding sites for a number of transcription
factors—for example, for nuclear factor of kappa light
polypeptide gene enhancer in B-cells 1 (NFKB1) and for H6
family homeobox 1 (HMX1). The annotation cluster with the
highest enrichment score for the analysis of the D18
downregulated genes also contained genes with potential
binding sites for transcription factors—for example, forkhead
box C1 (FOXC1) and forkhead box L1 (FOXL1) (Supple-
mental Table S6). Furthermore, functional terms related to
secreted proteins and proteins of the extracellular matrix
(ECM), cell adhesion, regulation of transcription, neuronal
differentiation, and homeobox proteins were found as over-
represented for the genes downregulated on D18 of pregnancy
(Supplemental Table S6).
Effects of Treatment with Human IFNA2 on Endometrial
Gene Expression
The analysis of microarray expression data revealed that one
PLAC sample showed elevated expression levels for typical
type I IFN-induced genes (e.g. ISG15, MX1, MX2, and IFIT2).
This elevated expression was confirmed by qPCR (data not
shown). This animal had no obvious fever, mastitis, or other
infections with clinical symptoms. However, a subclinical
infection or an individual reaction to the transfer of the placebo
lipid extrudate cannot be excluded. Furthermore, one cRNA
sample of the IFNA treatment group turned out to be a
technical outlier. Therefore, Limma analysis was performed
with three biological replicates per group. Statistical analysis
resulted in 236 differentially expressed probe sets for IFNA
versus PLAC (221 with higher and 15 with lower levels in
IFNA) and 212 differentially probe sets for IFNA versus
CONT (173 with higher and 39 with lower levels in IFNA) at
an FDR of 5% and a fold-change of 1.5 or greater. No
significant differences were found between PLAC and CONT
(adjusted P value . 0.6). The overlap between the three
contrasts is shown in the Venn diagram in Figure 1A. A
consistent overlap was found between IFNA versus PLAC and
between IFNA versus CONT for the probes with higher levels
in the IFNA group. Of note, only six probes were significantly
reduced in both IFNA versus PLAC and IFNA versus CONT.
Expression patterns based on the probes showing differential
expression were further investigated by a cluster analysis of the
individual samples. The results of this analysis are shown in
TABLE 3. Selected results of Gene Set Enrichment Analysis of the Day 18 pregnant vs. control data set.







No. genes matching top
300 or bottom (*) 100e
Percent
(%)f
D15 of pregnancy upregulated (this study) 246 3.63 ,0.001 ,0.001 653 189 76.8
D16 of pregnancy upregulated Forde et al. [28] 294 3.63 ,0.001 ,0.001 928 204 69.4
D17 of pregnancy upregulated Walker et al. [30] 355 3.62 ,0.001 ,0.001 785 229 64.5
D18 of pregnancy upregulated Klein et al. [25] 69 3.10 ,0.001 ,0.001 296 51 73.9
D20 of pregnancy upregulated Mansouri-Attia et al. [29] 36 2.40 ,0.001 ,0.001 511 16 44.4
Browne IFN-responsive genes [90] 52 2.85 ,0.001 ,0.001 794 42 80.8
D15 of pregnancy downregulated (this study) 59 2.72 ,0.001 ,0.001 1571 24* 40.7
D16 of pregnancy downregulated Forde et al. [28] 140 2.86 ,0.001 ,0.001 2176 37* 26.4
D17 of pregnancy downregulated Walker et al. [30] 235 2.56 ,0.001 ,0.001 2207 38* 16.2
D20 of pregnancy downregulated Mansouri-Attia et al. [29] 42 0.84 0.902 1.000 1380 2* 4.8
Reactome peptide chain elongation 80 2.31 ,0.001 0.001 3696 6* 7.5
a Number of genes in a gene set that matched with the ranked gene list.
b NES, normalized enrichment score.
c FDR, false discovery rate.
d FWER, family-wise error rate.
e Number of genes matching with the top 800 or the bottom 400 (designated by italics and an asterisk) of pre-ranked gene list.
f Percentage in relation to the size of the gene set.









FIG. 1. Results of IFNA2 treatment and comparison to gene expression on D15 and D18 of pregnancy. A) Venn diagram of Limma results of the IFNA2
administration experiment. The overlap of the differentially expressed probe sets for the calculated contrasts is shown. Significant thresholds were 5% for
FDR and 1.5 for fold-change. CONT vs. PLAC, PBS versus placebo; IFNAvs. CONT, human IFNA2 versus control (PBS); IFNA vs. PLAC, IFNA2 vs. placebo
(extrudates without IFNA2). B) Cluster analysis of the differentially expressed probe sets resulting from the IFNA2 administration experiment. Normalized
expression values (after vsn normalization) were divided by the mean over all samples (mean-centered values). Numbers indicate internal ID of individual
heifers. CONT, treatment with PBS; IFNA, treatment with human IFNA2; PLAC: treatment with extrudates without IFNA2. C) Cluster analysis of the genes
differentially expressed after treatment with human IFNA2 and/or on D15 of pregnancy. Log
2










Figure 1B. Expression patterns of the individual samples
within the same treatment group were very similar. The sample
tree showed no clear separation of PLAC and CONT,
corresponding to the results of the statistical analysis. Slight
differences in expression patterns between PLAC and CONT
were observed, particularly for the probes with lower levels in
the IFNA group. Based on these results, the data from the
contrast IFNA versus PLAC were used for the comparison with
the results from the analysis during early pregnancy.
Annotation of the differential probe sets for the contrast IFNA
versus PLAC revealed 173 genes with higher levels and 12
genes with lower levels in IFNA samples (Supplemental Table
S3).
Comparison of Effects of IFNA2 Treatment to Gene
Expression Changes at D15 and D18 of Pregnancy
For the DEGs obtained at D15 of pregnancy and from IFNA
versus PLAC, a cluster analysis was performed based on the
log
2
fold-changes for IFNA versus PLAC, IFNA versus
CONT, and D15 and D18 of pregnancy versus cyclic controls
(Fig. 1C). Almost all genes with higher expression levels (Fig.
1C, red) in IFNA versus PLAC also had higher levels in 15P
and 18P samples compared to nonpregnant cyclic samples.
Table 4 shows a comparison of fold-changes of typical ISGs.
Fold-changes were very similar between IFNA and PLAC and
at D15 and D18 of pregnancy (pregnant/cyclic). In contrast, a
number of genes showed expression differences in early
pregnancy (15P vs. 15C and/or 18P vs. 18C) but not after
IFNA2 treatment.
Table 5 shows results of the analysis of selected genes by
qPCR. Again, similar expression differences were found after
IFNA2 treatment and during early pregnancy for typical
immune-stimulated genes (upper part of Table 5). Furthermore,
differences in the response to IFNA2 treatment compared to
D15 and/or D18 of pregnancy were confirmed for genes
upregulated after IFNA2 treatment but not or to a lesser extent
on D15 and D18, respectively (middle part of Table 5), and for
genes upregulated on D15 and/or D18 of pregnancy but not
after IFNA2 treatment (bottom part of Table 5).
The DEGs of IFNA versus PLAC and of 15P versus 15C
(Supplemental Table S3) were then filtered to find genes
differentially expressed after IFNA2 treatment but not on D15
of pregnancy and genes differentially expressed at D15 of
TABLE 4. Comparison of effects of human IFNA2 and Days 15 and 18 of pregnancy on endometrial gene expression for typical IFN-stimulated genes
(fold change .5 for IFNA vs. PLAC).
Entrez Gene ID Gene symbol Gene description
Fold change*
IFNA vs. PLAC IFNA vs. CONT 15P vs. C 18P vs. C
280873 MX2 Myxovirus (influenza virus) resistance 2 (mouse) 42.6 46.4 40.0 47.6
281871 ISG15 ISG15 ubiquitin-like modifier 30.1 33.5 37.9 29.9
618737 BST2 Bone marrow stromal cell antigen 2 20.4 20.4 23.2 25.9
506415 RSAD2 Radical S-adenosyl methionine domain containing 2 18.6 18.1 28.7 30.9
100139670 IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 17.2 16.7 27.6 28.9
508347 LOC508347 Interferon-induced protein 44-like 15.3 13.3 14.2 17.2
508348 IFI44 Interferon-induced protein 44 14.0 12.9 18.0 17.3
506604 ISG20 Interferon stimulated exonuclease gene 20kDa 12.7 12.2 9.1 20.6
521795 SLFN11 Schlafen family member 11 12.6 12.5 7.7 12.1
511001 CLEC4F C-type lectin domain family 4, member F 12.2 12.0 7.6 14.0
514205 SAMD9 Sterile alpha motif domain containing 9 11.1 9.9 14.4 16.1
515202 USP18 Ubiquitin specific peptidase 18 10.8 9.2 12.6 12.1
539759 SIGLEC1 Sialic acid binding Ig-like lectin 1, sialoadhesin 9.6 6.7 4.8 11.3
654488 OAS1 20,50-Oligoadenylate synthetase 1, 40/46kDa 9.4 9.1 12.7 9.4
280872 MX1 Myxovirus (influenza virus) resistance 1 8.2 8.6 12.5 6.8
613313 GBP4 Guanylate binding protein 4 8.0 5.8 6.0 7.0
497204 UBA7 Ubiquitin-like modifier activating enzyme 7 7.8 6.4 9.6 9.3
512913 IFI6 Interferon, alpha-inducible protein 6 7.6 8.1 5.5 6.2
532442 RTP4 Receptor (chemosensory) transporter protein 4 7.4 6.7 10.1 9.2
509283 RNF213 Ring finger protein 213 6.9 6.8 7.6 7.1
509740 XAF1 XIAP associated factor 1 6.9 6.5 6.4 8.1
506759 IFI16 Interferon, gamma-inducible protein 16 6.7 6.0 5.6 6.9
507549 TIMD4 T-cell immunoglobulin and mucin domain containing 4 6.6 6.6 3.1 7.6
614555 EPSTI1 Epithelial stromal interaction 1 (breast) 6.4 5.6 6.8 10.8
767910 PLAC8 Placenta-specific 8 6.0 4.1 5.1 7.3
527520 HERC6 Hect domain and RLD 6 6.0 6.1 3.2 6.1
535490 IFIH1 Interferon induced with helicase C domain 1 5.6 5.1 5.4 6.2
100138545 PML Promyelocytic leukemia 5.5 5.2 3.9 5.8
508333 ZBP1 Z-DNA binding protein 1 5.4 5.4 7.9 9.9
617420 ISG12(B) TLH29 protein precursor-like 5.4 5.2 1.5 2.7
514978 LOC514978 Lipopolysaccharide-binding protein-like 5.4 5.6 2.7 13.5
540789 PARP14 Poly (ADP-ribose) polymerase family, member 14 5.1 5.2 5.8 6.6
508378 LGP2 RNA helicase LGP2 5.1 5.1 5.9 5.4
504760 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 5.1 4.3 5.8 5.8
508877 PNPT1 Polyribonucleotide nucleotidyltransferase 1 5.0 4.6 5.3 5.6
509855 IRF9 Interferon regulatory factor 9 5.0 4.7 5.9 4.8
* Adjusted P values for all listed contrasts ,0.05.
3
FDR and 1.5 for fold-change. 15P vs. 15C, D15 pregnant versus cyclic; 18P vs. 18C, D18 pregnant versus cyclic. Cluster diagrams were produced using
Multi Experiment Viewer [89]. In B and C, red indicates values higher than the mean of all samples, and blue indicates values lower than the mean.









pregnancy but not after IFNA2 treatment. Genes effected by
IFNA2 but not by pregnancy could indicate differences in the
endometrial response to IFNA2 and IFNT and/or modulation of
IFN response by additional conceptus-derived factors. Genes
differentially expressed in pregnant endometrium but not after
IFNA2 treatment could indicate specific effects of IFNT and/or
effects of additional embryonic factors.
The DAVID functional annotation clustering of the genes
that are differentially expressed for IFNA versus PLAC but not
for 15P versus 15C (heatmap of expression differences shown
in Fig. 2A) revealed quantitatively enriched functional
categories mostly related to immune response terms, such as
regulation of immune system process, innate immune response,
positive regulation of cytokine production, and regulation of T
cell activation (Supplemental Table S7). Furthermore, cocita-
tion analysis of biological keywords (CoPub) found signifi-
cantly enriched keywords, such as inflammation; phagocytosis;
antigen presentation; cell death, apoptosis; cytokine secretion,
cytokine production, cytokine biosynthesis; T-cell and B-cell
activation, proliferation, and differentiation; and macrophage
activation (Supplemental Table S8). Correspondingly, the
Kyoto Encyclopedia of Genes and Genomes pathways, which
were hit with at least three genes, were also all immune-related:
systemic lupus erythematosus, Staphylococcus aureus infec-
tion, cytokine-cytokine receptor interaction, complement and
coagulation cascades, phagosome, osteoclast differentiation,
and chemokine signaling pathway (Supplemental Table S9).
A heatmap of expression differences for genes differentially
expressed for 15P versus 15C but not or to a lesser extent after
IFNA2 treatment is shown in Figure 2B. The DAVID analysis
of these genes revealed only two significantly (P , 0.05)
enriched annotation clusters, one related to transport and one
containing genes coding for transmembrane proteins (Supple-
mental Table S10). CoPub analysis identified no significantly
enriched keywords associated with these genes (P . 0.130).
When setting no P-value cut-off, many different biological
keywords were obtained, such as transport, tumor-related
keywords, homeostasis, metabolism, angiogenesis, growth, cell
differentiation, and apoptosis (Supplemental Table S11). Kyoto
Encyclopedia of Genes and Genomes pathways that were hit
with at least three genes were metabolic pathways, cytokine-
cytokine receptor interaction, and N-glycan biosynthesis
(Supplemental Table S12).
Localization of mRNA Expression for Selected Genes by In
Situ Hybridization
Four genes—jumonji C domain containing histone deme-
thylase 1 homolog D (JHDM1D), indoleamine 2,3-dioxyge-
nase 1 (IDO1), fatty acid-binding protein 3, muscle and heart
(mammary-derived growth inhibitor) (FABP3), and dickkopf
homolog 1 (DKK1)—were selected for in situ localization of
mRNA expression on D13, D16, and D19 of pregnancy and
corresponding days of the estrous cycle (Fig. 3). These genes
TABLE 5. Validation of expression of selected genes by quantitative real-time RT-PCR (qPCR).
Gene Method
Fold change P value*
IFNA/PLAC D15 P/C D18 P/C D15 P/C D18 P/C
IFI16 qPCR 8.8 4.4 13.3 0.026 0.003
Array 6.7 5.6 6.9 0.001 ,0.001
IFI44 qPCR 21.7 16.7 39.7 ,0.001 ,0.001
Array 14.0 18.0 17.3 ,0.001 ,0.001
IFIT2 qPCR 13.8 8.3 21.9 0.024 ,0.001
Array n.d. n.d. 2.2 n.d. ,0.001
ISG15 qPCR 154.6 14.9 84.4 ,0.001 ,0.001
Array 30.1 37.9 29.9 0.001 ,0.001
MX1 qPCR 22.7 24.6 24.1 0.002 ,0.001
Array 8.2 12.5 6.8 0.004 ,0.001
MX2 qPCR 160.8 101.1 229.1 0.001 ,0.001
Array 42.6 40.0 47.6 ,0.001 ,0.001
B2M qPCR 4.0 1.2 2.8 0.100 ,0.001
Array 2.5 1.6 2.2 0.075 0.002
C2 qPCR 20.4 3.3 11.4 0.031 ,0.001
Array 3.1 1.3 4.0 0.140 ,0.001
IDO1 qPCR 72.3 1.4 29.5 0.200 ,0.001
Array 47.1 2.9 17.2 0.096 ,0.001
TLR7 qPCR 2.8 1.7 2.3 0.060 0.080
Array 2.6 n.d. 1.7 n.d. 0.003
CDH1 qPCR 1.1 1.7 1.8 0.043 0.028
Array 1.0 1.6 1.3 0.032 0.046
DKK1 qPCR 3.2 4.4 7.9 0.014 ,0.001
Array 2.1 4.1 4.5 0.046 0.002
FABP3 qPCR 1.3 4.2 27.2 0.015 ,0.001
Array 1.6 5.6 16.0 0.012 0.001
MFAP5 qPCR 1.2 2.9 1.3 0.006 0.635
Array 1.4 3.1 1.1 0.015 0.889
MGAT4A qPCR 1.1 1.3 2.6 0.357 0.023
Array 1.5 2.5 3.8 0.032 0.006
PLET1 qPCR 1.5 16.9 106.4 0.007 ,0.001
Array 1.4 10.8 122.6 0.014 ,0.001
PTHLH qPCR 1.0 3.1 1.1 0.009 0.697
Array 1.2 2.3 1.1 0.018 0.817
SLC39A2 qPCR 1.2 2.9 1.6 0.025 0.544
Array 1.1 2.4 2.1 0.030 0.175










were chosen due to their differences in gene expression
changes during pregnancy and in response to treatment with
human IFNA2 and based on their known or projected
functions. JHDM1D mRNA was mainly detected in the
luminal and glandular epithelium during pregnancy, but it
was also detected to a lesser extent during the estrous cycle.
IDO1 mRNA was observed in immune cells around blood
vessels and in myometrium. Expression of FABP3 mRNA was
detected in LE and superficial glandular epithelia. Interestingly,
FABP3 decreased from D13 to D19 of the estrous cycle but not
in pregnant heifers. DKK1 mRNA was predominantly
expressed in stromal cells at D16 and D19 of pregnancy.
DISCUSSION
The present study was conducted to analyze endometrial
responses to the presence of a conceptus at the level of gene
expression during the preimplantation phase, with particular
emphasis on specific effects of IFNT and/or additional
conceptus-derived modulatory factors in comparison to a
typical type I IFN, such as IFNA. In addition to their well-
known function in innate immunity via their pleiotropic effects
on somatic cells, type I IFNs also play a role in adaptive
immune responses, particularly in regulation of CD4þ and
CD8
þ
T cells [54]. During pregnancy, activation of the specific
immune system in the uterus is not desired and has to be
modulated to avoid harming the embryo/conceptus. This could
be achieved by specific effects of IFNT compared to IFNA2 or
by modulatory factors secreted by the conceptus. To
investigate differences in the effects of a typical type I IFN
and the presence of a conceptus with its secreted factors
(mainly IFNT) on the bovine endometrium, gene expression
studies of endometrial tissue samples were performed during
early pregnancy and after administration of IFNA2, and the
results were compared.
Rod-shaped lipid twin-screw extrudates containing human
IFNA2 were used to achieve uterine IFNA2 release in a
sustained manner over the time of administration [34] to mimic
the secretion of IFNT from trophoblast cells of the conceptus
during the window of maternal recognition of pregnancy. The
proposed antiviral activity released over the 2 days was based
on amounts used in previous studies with sheep [19, 38, 39],
and extrudates were adjusted accordingly in the in vitro release
experiments. To prove release in vivo, antiviral activity was
measured in uterine flushings. Antiviral activity was at least
one order of magnitude lower compared to the release of
extrudates in vitro. This can be explained by limited diffusion
in vivo in the uterine lumen, IFNT bound by the endometrium,
and IFNT diffusing into the uterine glands; furthermore, IFNT
has been shown to be released from the uterus via the uterine
vein [55]. Uterine flushings from D12, D15, and D18 of
pregnancy were also analyzed for antiviral activity by
Groebner et al. [53]. On D12, no antiviral activity was
detectable, which is in line with the results of Short et al. [56].
For the D15 pregnant heifers used in the present microarray
study, no uterine flushings were available. Considering the
D15 pregnant heifers with similar conceptus sizes studied by
Groebner et al. [53], antiviral activity was approximately 3000
IU/flush. For the D18 pregnant heifers, mean antiviral activity
was 180 000 IU/flush. The obtained antiviral activities appear
to be lower than reported earlier, because Short et al. [56]
found 105 IU/flush on D15 and 107 IU/flush on D17 and
Loureiro et al. [57] found up to 6 3 106 IU/flush on D15.
Altogether, the observed antiviral activity in uterine flushings
after the 2 days of IFNA2 administration were in a
physiological range comparable to antiviral activity in the
uterine lumen during early pregnancy due to production of
IFNT by the elongating conceptus.
Analysis of D12, D15, and D18 of Pregnancy
The microarray analysis of endometrial tissue samples
collected during the preimplantation phase did not reveal
differential gene expression on D12 of pregnancy, which is in
line with recently published data [28] showing no differences
on D13 and the finding that no antiviral activity was detectable
in uterine flushings from D12 of pregnancy [53]. Although
these findings reveal no detectable response in the whole
endometrial tissue, a local response in the LE near the D12
conceptus cannot be excluded. Because a number of micro-
array studies of bovine endometrium during early pregnancy
have been published, the present results obtained for D15 and
D18 of pregnancy were compared to studies conducted on D16
[28], D17 [30], D18 (genes from Klein et al. [25] and from the
present study), and D20 [29] of pregnancy. Overall, a
substantial overlap was found for the D15 and D18 of
pregnancy upregulated genes with the other studies, although
different microarray platforms were used and differences in the
data analysis existed. The lowest overlap was observed with
the genes upregulated on D20 of pregnancy, a time point after
initiation of implantation. However, a different microarray was
used for the study by Mansouri-Attia et al. [29], and only the
top 100 DEGs were available in the supplemental data, which
could be used for GSEA. The highest overlap was obtained for
the D15 upregulated genes with the D18 upregulated genes
found in the present study, indicating the early response to
IFNT on D15 and a full response on D18. In contrast, a much
lower overlap was found for the downregulated genes,
particularly in the GSEA for D15. Considering that the
treatment with human IFNA2 resulted predominantly in
stimulation of gene expression, IFNT probably results mainly
in upregulation of gene expression, and downregulation could
be an effect of the interaction with P4 action on the
endometrium, which differs with cycle stage. Because after
D16 the serum P4 concentrations start to decrease, the effects
of pregnancy and different P4 concentrations in the pregnant
and control groups could result in a mixture of pregnancy and
hormone-level effects. To reduce cycle stage effects, heifers
with high P4 concentrations were selected for the D18 control
group in the present study. Different biological models (heifers
or lactating cows) and different P4 concentrations in the cyclic
control groups (not stated in the other studies) could be a
reason for the lower overlap found for the downregulated
genes. The overlap of the downregulated genes was also
analyzed between the other studies (D16, D17, and D20) and
found to be very low.
The characterization of the DEGs using DAVID functional
annotation clustering of upregulated genes revealed for both
D15 and D18 of pregnancy mainly overrepresented functional
categories related to the response to IFNT. The comparison of
the gene contents of these categories showed some distinct
differences, indicating the existence of early and late IFN
response genes, as suggested previously by Forde et al. [28].
For example, genes of the suppressor of cytokine signaling
(SOCS) family members 1, 3, 4, and 6, which have been
described as negative regulators if IFNT signaling in ovine
endometrium [58], were found on D18. Likewise, genes for the
cathepsin family members C, H, L1, S, and Z were identified as
upregulated only on D18 of pregnancy. In ovine endometrium,
CTSH, CTSK, CTSL, CTSS, and CTSZ have been described as
ISGs [59]. DAVID analysis of the downregulated genes on
D18 of pregnancy (higher levels in cyclic controls) revealed a


















number of functional categories related to ECM and protein
secretion, in line with previous results from a study of bovine
endometrium during the estrous cycle [60]. Among the most
significantly enriched functional groups were members of the
homeobox family B (B2, B4–B8). HOXB genes have been
described in the context of hematopoietic development and
differentiation [61], and so far, regulation of these genes has
not been described in the endometrium.
Comparison of Gene Expression During Early Pregnancy
and after IFNA2 Treatment
Due to the massive induction of ISGs on D15 and D18 of
pregnancy, other, more specific gene expression changes may
be covered and so remain unidentified. To mask the typical
IFN-induced genes, the data from D15 and D18 of pregnancy
were compared to the effects of intrauterine application of
human IFNA2. Administration of IFNA2 extrudates from D14
to D16 of the estrous cycle resulted in a specific response at the
level of gene expression in the endometrium, because no
significant differences were found between PLAC and CONT.
The number of DEGs was lower compared to D15 and D16 of
pregnancy [28], but more upregulated than downregulated
genes were observed, similar to the results obtained on D15 of
pregnancy. Comparison of fold-upregulation of typical ISGs
showed very similar effects after IFNA2 treatment and at D15
and D18 of pregnancy, indicating that the administered dose of
human IFNA2 was in a range to elicit a physiological response
of the endometrium. Besides these similar responses, distinct
differences were observed—namely, genes with significant
expression differences after IFNA2 administration but not at
D15 of pregnancy, and vice versa. These genes were analyzed
with different bioinformatics tools to characterize their
functions.
Genes Showing Stronger Upregulation after IFNA2
Administration Compared to D15 and D18 of Pregnancy
Most of the genes that showed stronger upregulation in
response to IFNA2 compared to early pregnancy are known to
be involved in different immune functions, indicating an
attenuated response of the maternal immune system during
early pregnancy. For example, genes coding for the three
subcomponents of complement component 1q—the initiator of
the classical complement pathway, other complement genes,
and genes coding for factors interacting with complement
proteins—were induced by IFNA2 but not on D15 of
pregnancy. Furthermore, DAVID and CoPub analyses revealed
that many of the genes induced by IFNA2 but not or to a lesser
extent during pregnancy are related to the regulation of T cells
and dendritic cells. For example, adenylate cyclase 7 (ADCY7)
has been shown to be involved in regulation of antibody
responses toward both T cell-independent and T cell-dependent
antigens, regulation of memory T cells, and regulatory T cells
[62, 63]. The GTPase IMAP (immunity associated protein)
family members 5, 6, and 8 (GIMAP5, GIMAP6, and GIMAP8)
were shown to regulate the survival of T cells during
development, selection, and T-cell homeostasis and the
development of natural killer and natural killer T cells [64,
65]. A distinct difference in gene expression was found for
IDO1. In mice, expression of Ido1 by trophoblast cells and
endometrial macrophages has been shown, leading to suppres-
sion of T-cell activity, preventing rejection of the allogeneic
concepti [66]. In bovine endometrium, mRNA expression in
cells located around blood vessels also suggests expression in
immune cells. In a recent study, a strong increase in IDO1
expression was observed in cultured bovine endometrial
stromal and glandular epithelial cells after treatment with
IFNT [67]. The lower increase in IDO1 mRNA observed on
D15 and D18 of pregnancy compared to the IFNA2 treatment
could be due to fine-tuned regulation of the maternal immune
system during early pregnancy. In addition to genes involved in
regulation of T cells, CoPub analysis revealed genes described
in the context of macrophage and B-cell activation for the
genes more induced by IFNA2 treatment compared to
pregnancy, such as allograft inflammatory factor 1 (AIF1),
colony-stimulating factor 1 receptor (CSF1R), and TLR7.
Altogether, the immune-related functions of the genes showing
attenuated regulation in pregnant endometrium compared to
IFNA2 treatment indicate specific effects of IFNT and/or
effects of modulatory conceptus-derived factors, which are
needed to prevent improper reactions of the maternal immune
system.
Genes Not Regulated after IFNA2 Administration but on
D15 and/or D18 of Pregnancy
Both DAVID and CoPub analyses of the genes found as
differentially expressed only during pregnancy showed that
these genes were very diverse in terms of biological functions.
Except for a DAVID functional annotation cluster related to
transport, no specific quantitatively enriched processes or
functions were found. The category transport contained several
members of the solute carrier gene family, including SLC2A1
(glucose transporter), SLC7A3 (cationic amino acid transport-
er), SLC12A2 (sodium, potassium, and chloride transporter),
SLC25A5 (mitochondrial carrier, adenine nucleotide trans-
locator), SLC25A33 (mitochondrial carrier), SLC39A2 (zinc
transporter), and SLC40A1 (iron transmembrane transporter).
The two mitochondrial transporters, SLC25A5 and
SLC25A33, have a role in cellular energy metabolism [68]
and mitochondrial maintenance [69]. For the expression of the
glucose transporter gene SLC2A1, regulation by conceptus
prostaglandins has been shown recently in the ovine uterus
[70], indicating that additional conceptus-derived factors
influence the endometrial gene expression. This idea is further
supported by a study of prostaglandins in the lumen of the
bovine uterus at D12, D15, and D18 of the estrous cycle and of
pregnancy showing increased levels of prostaglandins at D15
and D18 of pregnancy, from which a considerable part is most
probably of embryonic origin [47]. Also, other studies in sheep
indicate the role of additional conceptus-derived signaling
3
FIG. 2. Expression differences of selected genes after treatment with human IFNA2 and on D15 and D18 of pregnancy. A) Genes with significant
differences after treatment with human IFNA2 but not on D15 of pregnancy. Genes downregulated after IFNA2 treatment are shown at the top, genes
upregulated after IFNA2 treatment but not on D15 of pregnancy in the middle, and genes upregulated after IFNA2 treatment but not on D15 and D18 of
pregnancy at the bottom. B) Genes with significant differences on D15 of pregnancy but not after treatment with human IFNA2. Genes downregulated on
D15 of pregnancy are shown at the top, genes upregulated only on D15 of pregnancy in the middle, and genes upregulated on D15 and D18 of pregnancy
but not after IFNA2 treatment at the bottom. CONT vs. PLAC, PBS control versus placebo; IFNA vs. CONT: IFNA2 versus control (PBS); IFNA vs. PLAC,
human IFNA2 versus placebo (extrudates without IFNA2); 15P vs. 15C, D15 pregnant versus cyclic; 18P vs. 18C, D18 pregnant versus cyclic. Heatmaps
were produced using Multi Experiment Viewer [89] and show log
2
-fold changes.









molecules in modulation of endometrial gene expression [71],
such as prostaglandin produced by the preimplantation ovine
conceptus [72]. The increased SLC7A3 expression agrees with
the results of a recent study in which higher levels of cationic
and other (particularly branched chained) amino acids, were
found in uterine flushings from pregnant heifers [73].
The genes showing the strongest upregulation at D15 and
D18 of pregnancy but no significant change after IFNA2
treatment were FABP3 and placenta-expressed transcript 1
protein (PLET1). FABP3 functions in modulation of cell
growth and proliferation [74]. In situ hybridization showed
specific expression in the LE, suggesting a regulatory role in
these cells. Little is known about PLET1, but based on a study
by Depreter et al. [75], this gene could also have a role in the
development of epithelial cells. For dickkopf homolog 1
(DKK1), coding for an inhibitor of WNT signaling, mRNA
expression was found in stromal cells on D16 and D19 of
pregnancy. This finding is in line with those studies in human
endometrium, in which induction of DKK1 expression by P4
[76] and specific expression during the window of implantation
[77] have been shown.
In addition to the genes SLC39A2 and SLC40A1 coding for
various transporters (see above), a number of genes with very
different functions showed elevated expression levels com-
pared to nonpregnant cyclic controls only on D15 of pregnancy
and not on D18 or after IFNA2 treatment. These genes could
have specific functions in supporting conceptus growth during
this phase and/or possibly in the context of maternal
recognition of pregnancy. Of these genes, microfibrillar
associated protein 5 (MFAP5) has been shown to promote
angiogenic cell spouting in vitro by antagonizing Notch
signaling pathways in endothelial cells [78], suggesting a role
of MFAP5 in endometrial vascular remodeling. A second gene,
microtubule-associated tumor suppressor 1 (MTUS1, alias
ATIP), was also described in the context of vascular
remodeling [79]. Two genes, sterol O-acyltransferase 1
(SOAT1) and hydroxysteroid (17-beta) dehydrogenase 13
(HSD17B13), are involved in steroidogenesis [80, 81]. For
parathyroid hormone-like hormone (PTHLH), a role in early
pregnancy in the rat has been shown by antagonization of
PTHLH action leading to fetoplacental growth restriction [82].
Trafficking protein, kinesin-binding 2 (TRAK2, alias GRIF1) is
a further potentially interesting gene, because a regulatory role
in epidermal growth factor receptor (EGFR) degradation has
been shown [83] and EGFR is involved in oxytocin-induced
PGF2a production [84].
Furthermore, a number of genes coding for transcription
factors were found with lower expression levels in pregnant
endometrium, including three genes of the HOXB transcription
factor family. Ectopic expression of HOXB8 in hematopoietic
progenitor cells has been shown to negatively regulate
granulocyte development in favor of macrophage development
[85]. HOXB4 has been involved in differentiation of
hematopoietic stem cells [86]. In addition, HOXB factors were
described as mediators of the steroid hormones during
endometrial cell development [87]. The gene nuclear factor
of activated T cells, cytoplasmic, calcineurin-dependent 3
(NFATC3) was also downregulated in pregnant endometrium
and has been described in the context of development and
differentiation of multiple cell types, including immune cells
[88]. In the context of the IFNA2-induced genes that were
involved in differentiation of immune cells, the lower levels of
these transcription factors in pregnant versus cyclic endome-
trium could be a mechanism to prevent unwanted effects of
IFNT.
FIG. 3. In situ localization of JHDM1D, IDO1, FABP3, and DKK1mRNA
expression in the bovine uterus on D13, D16, and D19 of pregnancy.
Cross-sections of the uterine wall from pregnant (P) heifers were
hybridized with radiolabeled antisense or sense bovine JHDM1D,
IDO1, FABP3, and DKK1 cRNAs and are presented under bright-field
and dark-field illumination after counterstaining with hematoxylin. Car,
caruncle; GE, glandular epithelium; Myo, myometrium; S, stroma. All










In summary, the present study showed that in cattle,
endometrial responses on the level of gene expression to the
presence of a conceptus are present as early as D15 of
pregnancy and that most of these genes are also differentially
expressed on D18 of pregnancy. The comparison of gene
expression changes in response to pregnancy with changes in
response to intrauterine application of human IFNA2 as a
classical type I IFN was used as an attempt to dissect the
response of the bovine endometrium to a classical type I IFN
and the presence of a conceptus that secretes the pregnancy-
specific IFNT and additional signaling molecules, such as PGs.
Though we found a broad overlap of the responses in the
pregnant and IFNA2 treatment groups to the corresponding
controls, distinct differences suggested a fine-tuned modulation
of pregnancy signaling by the conceptus. This could be due to
slightly different signaling via the IFN receptor by IFNT and/or
due to conceptus-derived factors other than IFNT. Furthermore,
the slow-release device (extrudate) developed in the present
study is an interesting tool for releasing defined amounts of
IFNs or other molecules in a physiological manner, which
could also allow one to specifically address maternal factors,
such as genetic background, parity, or metabolic disturbances,
in the early embryo-maternal cross-talk.
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